# Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

> **NCT04126525** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **RenJi Hospital** · enrollment: 53 (actual)

## Conditions studied

- Breast Cancer Female

## Interventions

- **DRUG:** Pyrotinib

## Key facts

- **NCT ID:** NCT04126525
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-18
- **Primary completion:** 2021-10-28
- **Final completion:** 2026-11
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04126525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04126525, "Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04126525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*